Page 1

remix therapeutics Modulating RNA Processing TO TARGET THE UNDRUGGABLE Investor Presentation July 2026 NON - CONFIDENTIAL Filed by Passage Bio , Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a - 12 under the Securities Exchange Act of 1934 Subject Company : Passage Bio , Inc. Filer's SEC File No .: 001-39231 Date : July 21 , 2026